Literature DB >> 22553141

In vitro and in vivo activity of 3-alkoxy-1,2-dioxolanes against Schistosoma mansoni.

Katrin Ingram1, Charles E Schiaffo, Wantanee Sittiwong, Evan Benner, Patrick H Dussault, Jennifer Keiser.   

Abstract

OBJECTIVES: Compounds characterized by a peroxidic skeleton are an interesting starting point for antischistosomal drug discovery. Previously a series of 3-alkoxy-1,2-dioxolanes, which are chemically stable cyclic peroxides, demonstrated significant in vitro activity against Plasmodium falciparum. We aimed to evaluate the potential of these compounds against Schistosoma mansoni and elucidate the roles of iron and peroxidic groups in activity.
METHODS: Drugs were tested against juvenile and adult stages of S. mansoni in vitro and in vivo. Selected structures were assessed in vitro against schistosomes in the presence of additional iron sources. In addition, drugs were tested in vitro and in vivo against Echinostoma caproni, a non-blood-feeding intestinal fluke. Finally, the activity of non-peroxidic analogues was evaluated.
RESULTS: Three dioxolanes displayed IC₅₀s ≤ 20.1 μM against adult schistosomes and values as low as 4.2 μM against newly transformed schistosomula. Nonetheless, only moderate, non-significant worm burden reductions were observed after treatment of mice harbouring adult infections. Drugs lacked activity against juvenile schistosomes in vivo. Two selected dioxolanes showed in vitro activity against E. caproni down to concentrations of 5 mg/L, but none of the compounds revealed in vivo activity. All tested non-peroxidic analogues lacked activity in vitro against both parasites.
CONCLUSIONS: Selected dioxolanes presented interesting in vitro activity, but low in vivo activities have to be overcome to identify a lead candidate. Although the inactivity of non-peroxidic analogues underlines the necessity of a peroxide functional group, incubation of adult schistosomes with additional iron sources did not alter activity, supporting an iron-independent mode of activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553141      PMCID: PMC3394440          DOI: 10.1093/jac/dks141

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica.

Authors:  Qingjie Zhao; Mireille Vargas; Yuxiang Dong; Lin Zhou; Xiaofang Wang; Kamaraj Sriraghavan; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

2.  Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial.

Authors:  Jennifer Keiser; Nicaise A N'Guessan; Koffi D Adoubryn; Kigbafori D Silué; Penelope Vounatsou; Christoph Hatz; Jürg Utzinger; Eliézer K N'Goran
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

Review 3.  In vitro and in vivo trematode models for chemotherapeutic studies.

Authors:  J Keiser
Journal:  Parasitology       Date:  2009-12-07       Impact factor: 3.234

4.  3-Alkoxy-1,2-Dioxolanes: Synthesis and Evaluation as Potential Antimalarial Agents.

Authors:  Charles E Schiaffo; Matthias Rottman; Sergio Wittlin; Patrick H Dussault
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

Review 5.  Human schistosomiasis.

Authors:  Bruno Gryseels; Katja Polman; Jan Clerinx; Luc Kestens
Journal:  Lancet       Date:  2006-09-23       Impact factor: 79.321

6.  Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro.

Authors:  Jennifer Keiser; Theresia Manneck; Mireille Vargas
Journal:  J Antimicrob Chemother       Date:  2011-05-20       Impact factor: 5.790

7.  Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum.

Authors:  Hong-Jun Li; Wei Wang; You-Zi Li; Guo-Li Qu; Yun-Tian Xing; Yong-Hui Tao; Jian-Ying Wei; Jian-Rong Dai; You-Sheng Liang
Journal:  Parasitol Res       Date:  2011-05-28       Impact factor: 2.289

8.  Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 1,2,4-trioxepane pairs: relationship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and antimalarial activity.

Authors:  Xiaofang Wang; Darren J Creek; Charles E Schiaffo; Yuxiang Dong; Jacques Chollet; Christian Scheurer; Sergio Wittlin; Susan A Charman; Patrick H Dussault; James K Wood; Jonathan L Vennerstrom
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

9.  Spiro- and dispiro-1,2-dioxolanes: contribution of iron(II)-mediated one-electron vs two-electron reduction to the activity of antimalarial peroxides.

Authors:  Xiaofang Wang; Yuxiang Dong; Sergio Wittlin; Darren Creek; Jacques Chollet; Susan A Charman; Josefina Santo Tomas; Christian Scheurer; Christopher Snyder; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2007-10-20       Impact factor: 7.446

Review 10.  Recent advances in the discovery of haem-targeting drugs for malaria and schistosomiasis.

Authors:  Katherine A de Villiers; Timothy J Egan
Journal:  Molecules       Date:  2009-08-04       Impact factor: 4.411

View more
  11 in total

Review 1.  Rearrangements of organic peroxides and related processes.

Authors:  Ivan A Yaremenko; Vera A Vil'; Dmitry V Demchuk; Alexander O Terent'ev
Journal:  Beilstein J Org Chem       Date:  2016-08-03       Impact factor: 2.883

2.  Pharmacokinetics of the Antischistosomal Lead Ozonide OZ418 in Uninfected Mice Determined by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Anna Leonidova; Mireille Vargas; Jörg Huwyler; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 3.  Synthesis of five- and six-membered cyclic organic peroxides: Key transformations into peroxide ring-retaining products.

Authors:  Alexander O Terent'ev; Dmitry A Borisov; Vera A Vil'; Valery M Dembitsky
Journal:  Beilstein J Org Chem       Date:  2014-01-08       Impact factor: 2.883

Review 4.  Repurposing drugs for the treatment and control of helminth infections.

Authors:  Gordana Panic; Urs Duthaler; Benjamin Speich; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-07-30       Impact factor: 4.077

Review 5.  Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions.

Authors:  Vera A Vil'; Ivan A Yaremenko; Alexey I Ilovaisky; Alexander O Terent'ev
Journal:  Molecules       Date:  2017-11-02       Impact factor: 4.411

6.  Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.

Authors:  Isabel Meister; Katrin Ingram-Sieber; Noemi Cowan; Matthew Todd; Murray N Robertson; Claudia Meli; Malay Patra; Gilles Gasser; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

Review 7.  Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.

Authors:  José T Moreira-Filho; Arthur C Silva; Rafael F Dantas; Barbara F Gomes; Lauro R Souza Neto; Jose Brandao-Neto; Raymond J Owens; Nicholas Furnham; Bruno J Neves; Floriano P Silva-Junior; Carolina H Andrade
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

8.  Re2O7-catalyzed reaction of hemiacetals and aldehydes with O-, S-, and C-nucleophiles.

Authors:  Wantanee Sittiwong; Michael W Richardson; Charles E Schiaffo; Thomas J Fisher; Patrick H Dussault
Journal:  Beilstein J Org Chem       Date:  2013-07-30       Impact factor: 2.883

9.  Development of an in vitro drug sensitivity assay based on newly excysted larvae of Echinostoma caproni.

Authors:  Gordana Panic; Katrin Ingram; Jennifer Keiser
Journal:  Parasit Vectors       Date:  2013-08-13       Impact factor: 3.876

10.  A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing.

Authors:  Sören Frahm; Anisuzzaman Anisuzzaman; Ulrich Fabien Prodjinotho; Nermina Vejzagić; Admar Verschoor; Clarissa Prazeres da Costa
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.